None listed
Conditions
Brief summary
The study is evaluating if a mobile phone based system can support patients to monitor their side effects, promote the delivery of evidence based self-care advice in a timely manner, and mediate the role of nurses to effectively provide real-time patient support. Who is it for? You may be eligible to join this study if you are aged over 18 years and have a diagnosis of one of three haematological cancers (Hodgkin's Lymphoma, Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukaemia), and are receiving four or more cycles of chemotherapy treatment. Trial details Participants in this study will be randomly (by chance) divided into one of two groups. Participants in one group will be required to complete a symptoms questionnaire twice daily on a device (morning and afternoon) from Cycle 1 - Cycle 4 of their chemotherapy treatment. The intervention nurse monitors symptoms and responds if any alerts are triggered. A red alert occurs if a patient reports a symptom requiring urgent attention, and an amber alert occurs if a patient reports a symptom requiring non-urgent attention. In the case of an alert, the nurse will contact the patient by phone and query the symptom, provide self-care advice and support. The device is a mobile phone enabled Android tablet. The handset contains an application that prompts patients to complete a side-effect assessment questionnaire by following instructions on the touch screen tablet. Normal phone functions are disabled. All patients will be provided with the android tablet device and SIM card for the trial. Participants in the second study group will continue to receive usual care, which involves the regular appointments with their medical treatment team, provision of hospital contact details and education about chemotherapy prior to first cycle.
Interventions
Telehealth system with nurse led support. Patients complete a symptoms questionnaire twice daily on a device(morning and afternoon) from Cycle 1 - Cycle 4 of chemotherapy. The questionnaires take approximately two minutes to complete each.
The intervention nurse monitors symptoms and responds if any alerts are triggered. A red alert occurs if a patient reports a symptom requiring urgent attention, a amber alert occurs if a patient reports a symptom requring non-urgent attention.
In the case of
Telehealth system with nurse led support. Patients complete a symptoms questionnaire twice daily on a device(morning and afternoon) from Cycle 1 - Cycle 4 of chemotherapy. The questionnaires take approximately two minutes to complete each. The intervention nurse monitors symptoms and responds if any alerts are triggered. A red alert occurs if a patient reports a symptom requiring urgent attention, a amber alert occurs if a patient reports a symptom requring non-urgent attention. In the case of an alert, the nurse will contact the patient by phone and query the symptom, provide self care and support. The device is a mobile phone enabled android tablet. The handset contains an application that prompts patients to complete a side-effect assessment questionnaire by following instructions on the touch screen tablet. Normal phone functions are disabled. All patients will be provided with the android tablet device and SIM card for the trial.
Sponsors
Peter MacCallum Cancer Centre
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Have a diagnosis of one of three haematological cancers (Hodgkin's lymphoma, Non-hodgkin's lymphoma or Chronic Lymphocytic Leukemia) Be receiving four or more cycles of chemotherapy treatment Be over 18 years of age
Exclusion criteria
Having a key cognitive psychological disorder as assessed by the treatment team Unable to speak/read/write English Participating in a clinical drug trial
Outcome results
None listed